Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to cut COPD attacks in patients with specific inflammation

NCT ID NCT07177339

Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tests whether adding depemokimab early to standard COPD treatment can reduce moderate to severe flare-ups in people with moderate to severe COPD who have type 2 inflammation. About 1,200 participants will receive either depemokimab or a placebo as an add-on therapy. The main goal is to see if the drug lowers the yearly rate of flare-ups requiring steroids, antibiotics, or hospitalization.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,196 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or eligible female participants * Eosinophilic phenotype measured using Blood Eosinophil Count (BEC) * Moderate to severe COPD, defined as * A clinically documented history of COPD for at least 1 year * A post-salbutamol Forced expiratory volume in one second (FEV1)/Forced vital capacity (FVC) ratio of less than (\<)0.70 and a post-salbutamol FEV1 greater than (\>)30 percent (%) and \<80% predicted normal values * Elevated risk for exacerbations, defined as * A well-documented history of only 1 moderate COPD exacerbation in the prior 12 months and * The presence of risk factors for future exacerbations/deterioration such as: * Modified Medical Research Council (mMRC) dyspnea score \>= 2 * COPD Assessment Test (CAT) \>= 15 * Post-bronchodilator FEV1 \< 50% predicted * Chronic bronchitis * Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years at Screening. * Dual (Inhaled corticosteroid (ICS)+ Long-acting beta2-adrenergic receptor agonist \[LABA\] or LABA+ Long-acting muscarinic receptor antagonist \[LAMA\]) or triple (ICS+LABA+LAMA) inhaler therapy as assessed by the investigator for at least 3 months * Body mass index (BMI) \>=16 kilograms per square meter (kg/m\^2) Exclusion Criteria: * The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of lung disease, and clinical manifestations of lung disease where primary diagnosis is not COPD are excluded * Participants with a current or prior physician diagnosis of asthma * Participants with childhood asthma are permitted, provided that childhood asthma has resolved before 18 years of age and has not recurred * Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease. * COPD severity: Participants with more than one moderate exacerbation or severe exacerbation in the past 12 months prior to Visit 1 * COPD stability: Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Visit 1 * Lung resection: Participants with a history of, or plan for lung volume reduction surgery/endobronchial valve procedure * Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1 * Chronic hypercapnia requiring non-invasive positive pressure ventilation (NIPPV) use including Bi-Level Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP) are excluded * Continuous oxygen: Participants requiring oxygen supplementation for COPD

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary disease, chronic obstructive are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary disease, chronic obstructive

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    121 sites in 13 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • GSK Investigational Site

    RECRUITING

    Newport Beach, California, 92663, United States

  • GSK Investigational Site

    RECRUITING

    Lakewood, Colorado, 80228-1813, United States

  • GSK Investigational Site

    RECRUITING

    Brandon, Florida, 33511, United States

  • GSK Investigational Site

    RECRUITING

    Crystal River, Florida, 34429, United States

  • GSK Investigational Site

    RECRUITING

    Doral, Florida, 33172, United States

  • GSK Investigational Site

    RECRUITING

    Greenacres City, Florida, 33467, United States

  • GSK Investigational Site

    RECRUITING

    Hialeah, Florida, 33012, United States

  • GSK Investigational Site

    RECRUITING

    Hollywood, Florida, 33024, United States

  • GSK Investigational Site

    RECRUITING

    Miami, Florida, 33125, United States

  • GSK Investigational Site

    RECRUITING

    Miami, Florida, 33126, United States

  • GSK Investigational Site

    RECRUITING

    Miami, Florida, 33176, United States

  • GSK Investigational Site

    RECRUITING

    Miami Lakes, Florida, 33016, United States

  • GSK Investigational Site

    RECRUITING

    Orlando, Florida, 32825, United States

  • GSK Investigational Site

    RECRUITING

    Cordele, Georgia, 31015, United States

  • GSK Investigational Site

    RECRUITING

    Dunwoody, Georgia, 30350, United States

  • GSK Investigational Site

    RECRUITING

    Boise, Idaho, 83702, United States

  • GSK Investigational Site

    RECRUITING

    Bowling Green, Kentucky, 42101, United States

  • GSK Investigational Site

    RECRUITING

    Lake Charles, Louisiana, 70605, United States

  • GSK Investigational Site

    RECRUITING

    Shreveport, Louisiana, 71105, United States

  • GSK Investigational Site

    RECRUITING

    Bangor, Maine, 04401, United States

  • GSK Investigational Site

    RECRUITING

    Allen Park, Michigan, 48101, United States

  • GSK Investigational Site

    RECRUITING

    Clarkston, Michigan, 48346, United States

  • GSK Investigational Site

    RECRUITING

    Dearborn, Michigan, 48126, United States

  • GSK Investigational Site

    RECRUITING

    Henderson, Nevada, 89052, United States

  • GSK Investigational Site

    RECRUITING

    Las Vegas, Nevada, 89123, United States

  • GSK Investigational Site

    RECRUITING

    Reno, Nevada, 89502, United States

  • GSK Investigational Site

    RECRUITING

    Winston-Salem, North Carolina, 27103, United States

  • GSK Investigational Site

    RECRUITING

    Edmond, Oklahoma, 73013, United States

  • GSK Investigational Site

    RECRUITING

    DuBois, Pennsylvania, 15801, United States

  • GSK Investigational Site

    RECRUITING

    West Chester, Pennsylvania, 19380, United States

  • GSK Investigational Site

    RECRUITING

    Greenville, South Carolina, 29607, United States

  • GSK Investigational Site

    RECRUITING

    Rock Hill, South Carolina, 29732, United States

  • GSK Investigational Site

    RECRUITING

    Knoxville, Tennessee, 37919, United States

  • GSK Investigational Site

    RECRUITING

    Dallas, Texas, 75254, United States

  • GSK Investigational Site

    RECRUITING

    DeSoto, Texas, 75115, United States

  • GSK Investigational Site

    RECRUITING

    Greenville, Texas, 75401, United States

  • GSK Investigational Site

    RECRUITING

    Houston, Texas, 77058, United States

  • GSK Investigational Site

    RECRUITING

    Houston, Texas, 77089, United States

  • GSK Investigational Site

    RECRUITING

    Houston, Texas, 77090, United States

  • GSK Investigational Site

    RECRUITING

    Katy, Texas, 77494, United States

  • GSK Investigational Site

    RECRUITING

    Mesquite, Texas, 75149, United States

  • GSK Investigational Site

    RECRUITING

    Stafford, Texas, 77477, United States

  • GSK Investigational Site

    RECRUITING

    Coffs Harbour, New South Wales, 2450, Australia

  • GSK Investigational Site

    RECRUITING

    Spearwood, Western Australia, 6163, Australia

  • GSK Investigational Site

    RECRUITING

    Haskovo, 6300, Bulgaria

  • GSK Investigational Site

    RECRUITING

    Montana, 3400, Bulgaria

  • GSK Investigational Site

    RECRUITING

    Rousse, 7002, Bulgaria

  • GSK Investigational Site

    RECRUITING

    Sofia, 1463, Bulgaria

  • GSK Investigational Site

    RECRUITING

    Sofia, 1510, Bulgaria

  • GSK Investigational Site

    RECRUITING

    Sofia, 1756, Bulgaria

  • GSK Investigational Site

    RECRUITING

    Kingston, Ontario, K7M 7E4, Canada

  • GSK Investigational Site

    RECRUITING

    Windsor, Ontario, N8X 1T3, Canada

  • GSK Investigational Site

    RECRUITING

    Shapingba, Chongqing Municipality, China

  • GSK Investigational Site

    RECRUITING

    Nanning, Guangxi, 530016, China

  • GSK Investigational Site

    RECRUITING

    Chengdu, Sichuan, 610500, China

  • GSK Investigational Site

    RECRUITING

    Chengdu, Sichuan, China

  • GSK Investigational Site

    RECRUITING

    Suining, Sichuan, 629018, China

  • GSK Investigational Site

    RECRUITING

    Beijing, 100020, China

  • GSK Investigational Site

    RECRUITING

    Beijing, 100034, China

  • GSK Investigational Site

    RECRUITING

    Changchun, 130021, China

  • GSK Investigational Site

    RECRUITING

    Changchun, 130041, China

  • GSK Investigational Site

    RECRUITING

    Changsha, 410013, China

  • GSK Investigational Site

    RECRUITING

    Chengdu, 610041, China

  • GSK Investigational Site

    RECRUITING

    Chongqing, 400042, China

  • GSK Investigational Site

    RECRUITING

    Dongguan, 523326, China

  • GSK Investigational Site

    RECRUITING

    Fujian, 350001, China

  • GSK Investigational Site

    RECRUITING

    Guangzhou, 510080, China

  • GSK Investigational Site

    RECRUITING

    Guangzhou, 510150, China

  • GSK Investigational Site

    RECRUITING

    Guangzhou, 510180, China

  • GSK Investigational Site

    RECRUITING

    Guilin, 541002, China

  • GSK Investigational Site

    RECRUITING

    Haikou, 570001, China

  • GSK Investigational Site

    RECRUITING

    Hangzhou, 310000, China

  • GSK Investigational Site

    RECRUITING

    Harbin, 150001, China

  • GSK Investigational Site

    RECRUITING

    Hefei, 230001, China

  • GSK Investigational Site

    RECRUITING

    Hohhot, 010050, China

  • GSK Investigational Site

    RECRUITING

    Huizhou, 516000, China

  • GSK Investigational Site

    RECRUITING

    Jiangmen, 529100, China

  • GSK Investigational Site

    RECRUITING

    Jiangmen, 529700, China

  • GSK Investigational Site

    RECRUITING

    Jinzhou, 121000, China

  • GSK Investigational Site

    RECRUITING

    Nanchang, 330000, China

  • GSK Investigational Site

    RECRUITING

    Nanchang, 330006, China

  • GSK Investigational Site

    RECRUITING

    Nanjing, 210009, China

  • GSK Investigational Site

    RECRUITING

    Qinhuangdao, 66000, China

  • GSK Investigational Site

    RECRUITING

    Shanghai, 200032, China

  • GSK Investigational Site

    RECRUITING

    Shanghai, 201199, China

  • GSK Investigational Site

    RECRUITING

    Shijiazhuang, 050000, China

  • GSK Investigational Site

    RECRUITING

    Shijiazhuang, 050051, China

  • GSK Investigational Site

    RECRUITING

    Taiyuan, 030001, China

  • GSK Investigational Site

    RECRUITING

    Taizhou, 317000, China

  • GSK Investigational Site

    RECRUITING

    Taizhou, 318000, China

  • GSK Investigational Site

    RECRUITING

    Ürümqi, 830054, China

  • GSK Investigational Site

    RECRUITING

    Weifang, China

  • GSK Investigational Site

    RECRUITING

    Wenzhou, 325000, China

  • GSK Investigational Site

    RECRUITING

    Xiamen, 361004, China

  • GSK Investigational Site

    RECRUITING

    Xinxiang, 453000, China

  • GSK Investigational Site

    RECRUITING

    Yinchuan, 750001, China

  • GSK Investigational Site

    RECRUITING

    Zunyi, 563114, China

  • GSK Investigational Site

    RECRUITING

    Berlin, 10625, Germany

  • GSK Investigational Site

    RECRUITING

    Berlin, 10717, Germany

  • GSK Investigational Site

    RECRUITING

    Frankfurt, 60389, Germany

  • GSK Investigational Site

    RECRUITING

    Frankfurt, 60596, Germany

  • GSK Investigational Site

    RECRUITING

    Mainz, 60549, Germany

  • GSK Investigational Site

    RECRUITING

    München, 81241, Germany

  • GSK Investigational Site

    RECRUITING

    Palaió Fáliro, Anatoliki Attiki, 175 62, Greece

  • GSK Investigational Site

    RECRUITING

    Ioannina, 45500, Greece

  • GSK Investigational Site

    RECRUITING

    Thessaloniki, Greece

  • GSK Investigational Site

    RECRUITING

    Ramat Gan, 52621, Israel

  • GSK Investigational Site

    RECRUITING

    Tel Aviv, 64239, Israel

  • GSK Investigational Site

    RECRUITING

    Gifu, 509-6134, Japan

  • GSK Investigational Site

    RECRUITING

    Mie, 515-8544, Japan

  • GSK Investigational Site

    RECRUITING

    Tokyo, 140-8522, Japan

  • GSK Investigational Site

    RECRUITING

    Ebdentown, Upper Hutt, 5018, New Zealand

  • GSK Investigational Site

    RECRUITING

    Rotorua, 3010, New Zealand

  • GSK Investigational Site

    RECRUITING

    Bialystok, 15-044, Poland

  • GSK Investigational Site

    RECRUITING

    Rzeszów, 35-051, Poland

  • GSK Investigational Site

    RECRUITING

    Barcelona, Spain

  • GSK Investigational Site

    RECRUITING

    Málaga, 29010, Spain

  • GSK Investigational Site

    RECRUITING

    Palma de Mallorca, 07010, Spain

  • GSK Investigational Site

    RECRUITING

    Bedford, MK40 2FG, United Kingdom

  • GSK Investigational Site

    RECRUITING

    Bradford, BD9 6RJ, United Kingdom

  • GSK Investigational Site

    RECRUITING

    Corby, NN17 2UR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.